RxDoctor Payments Data

Donni Jester

Family · Roswell, GANPI 1447231907

Payments from drug & device makers

$6,877in general payments, 2019–2025

Across 421 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$579
  • Lilly USA, LLC$551
  • Sanofi-aventis U.S. LLC$383
  • Xeris Pharmaceuticals, Inc.$371
  • IBSA Pharma Inc.$303
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,864100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,877 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$10,876
Medicare patients
86
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide277$408,687
Tresiba Flextouch U-200Insulin Degludec99$190,145
JardianceEmpagliflozin101$138,804
TrulicityDulaglutide95$138,647
FarxigaDapagliflozin Propanediol93$128,496
MounjaroTirzepatide81$124,879
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog49$49,070
Fiasp FlextouchInsulin Aspart (Niacinamide)36$45,032
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$44,603
JanuviaSitagliptin Phosphate35$41,649
RybelsusSemaglutide16$39,512
Soliqua 100-33Insulin Glargine/Lixisenatide16$36,743
Tresiba Flextouch U-100Insulin Degludec29$31,840
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$29,364
Bydureon BciseExenatide Microspheres12$26,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,231$462,822332 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$551$277,996195 claims
Boehringer IngelheimJardiance$142$138,804101 claims
AstraZenecaFarxiga$82$128,49693 claims
MerckJanuvia$42$41,64935 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$383$36,74316 claims
AbbVieSynthroid$196$18,803187 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$252$3,033360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →